{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:43:20Z","timestamp":1787165000788,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bioorg.2024.107988","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:27:53Z","timestamp":1732271273000},"page":"107988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities"],"prefix":"10.1016","volume":"154","author":[{"given":"Fan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-6759","authenticated-orcid":false,"given":"Ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4356-3615","authenticated-orcid":false,"given":"Hongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-0608","authenticated-orcid":false,"given":"Xumu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2024.107988_b0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107988_b0010","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bioorg.2024.107988_b0015","article-title":"Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives","volume":"10","author":"Ganesh","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tim.2016.09.001","article-title":"Molecular evolution of human coronavirus genomes","volume":"25","author":"Forni","year":"2017","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bioorg.2024.107988_b0025","unstructured":"14.9 Million excess deaths associated with the COVID-19 pandemic in 2020 and 2021. https:\/\/www.who.int\/news\/item\/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021."},{"key":"10.1016\/j.bioorg.2024.107988_b0030","unstructured":"COVID still 'very much with us' with 20% of tests positive in Europe, WHO warns. https:\/\/www.euronews.com\/health\/2024\/08\/07\/covid-still-very-much-with-us-with-20-of-tests-positive-in-europe-who-warns."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1074\/jbc.M408211200","article-title":"Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization: biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0040","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","article-title":"Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"issue":"5624","key":"10.1016\/j.bioorg.2024.107988_b0045","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1126\/science.1085953","article-title":"The genome sequence of the SARS-associated coronavirus","volume":"300","author":"Marra","year":"2003","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.bioorg.2024.107988_b0050","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107988_b0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0060","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"issue":"5626","key":"10.1016\/j.bioorg.2024.107988_b0065","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2024.107988_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.medntd.2022.100139","article-title":"Traditional Chinese Medicine is effective for COVID-19: A systematic review and meta-analysis","volume":"16","author":"Xu","year":"2022","journal-title":"Med. Novel Technol. Devices"},{"issue":"6575","key":"10.1016\/j.bioorg.2024.107988_b0075","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.bioorg.2024.107988_b0080","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Sim\u00f3n-Campos, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107988_b0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.2687","article-title":"Physiologically-based pharmacokinetic modeling-guided dose Management of Oral Anticoagulants when initiating nirmatrelvir\/ritonavir (Paxlovid) for COVID-19 treatment","volume":"112","author":"Wang","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107988_b0090","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/covid2080078","article-title":"Risk\/benefit profiles of currently approved oral antivirals for treatment of COVID-19: similarities and differences","volume":"2","author":"Corritori","year":"2022","journal-title":"COVID"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107988_b0095","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s11095-023-03538-5","article-title":"Physiologically-based pharmacokinetic modeling of PAXLOVID\u2122 with first-order absorption kinetics","volume":"40","author":"Sagawa","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2024.107988_b0100","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial","volume":"38","author":"Wang","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.bioorg.2024.107988_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102582","article-title":"Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"71","author":"Lu","year":"2024","journal-title":"Eclinicalmedicine"},{"key":"10.1016\/j.bioorg.2024.107988_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"Eclinicalmedicine"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107988_b0115","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cmdc.201900107","article-title":"Covalent inhibition in drug discovery","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107988_b0120","doi-asserted-by":"crossref","first-page":"e33024","DOI":"10.1097\/MD.0000000000033024","article-title":"A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)","volume":"102","author":"Yotsuyanagi","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107988_b0125","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1021\/acs.jmedchem.2c00624","article-title":"S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2","volume":"65","author":"Tyndall","year":"2022","journal-title":"J. Med. Chem."},{"issue":"679","key":"10.1016\/j.bioorg.2024.107988_b0130","doi-asserted-by":"crossref","first-page":"eabq4064","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.apsb.2023.08.004","article-title":"Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors","volume":"14","author":"Song","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107988_b0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","article-title":"Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro","volume":"9","author":"Hou","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107988_b0145","doi-asserted-by":"crossref","first-page":"12760","DOI":"10.1021\/acs.jmedchem.4c00739","article-title":"Discovery of novel nonpeptidic and noncovalent small molecule 3CLpro inhibitors as anti-SARS-CoV-2 drug candidate","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107988_b0150","doi-asserted-by":"crossref","first-page":"14986","DOI":"10.1021\/acs.jmedchem.4c00535","article-title":"Nonpeptidic irreversible inhibitors of SARS-CoV-2 main protease with potent antiviral activity","volume":"67","author":"Oneto","year":"2024","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2024.107988_b0155","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107988_b0160","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1021\/acsptsci.4c00369","article-title":"Novel alkynylamide-based nonpeptidic allosteric inhibitors for SARS-CoV-2 3-chymotrypsin-like protease","volume":"7","author":"Xue","year":"2024","journal-title":"ACS. Pharmacol. Transl. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107988_b0165","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2024.107988_b0170","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist\u2019s guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107988_b0175","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/jcm13020334","article-title":"Influence of seasonality and public-health interventions on the COVID-19 pandemic in northern Europe","volume":"13","author":"Quinn","year":"2024","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107988_b0180","doi-asserted-by":"crossref","first-page":"e1005","DOI":"10.1016\/S2214-109X(24)00090-1","article-title":"Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis","volume":"12","author":"Guo","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.bioorg.2024.107988_b0185","article-title":"The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper","volume":"11","author":"Belenkaya","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107988_b0190","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1042\/BCJ20230027","article-title":"Key allosteric and active site residues of SARS-CoV-2 3CLpro are promising drug targets","volume":"480","author":"Al Adem","year":"2023","journal-title":"Biochem. J."},{"issue":"10223","key":"10.1016\/j.bioorg.2024.107988_b0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1107\/S0021889809045701","article-title":"xia2: an expert system for macromolecular crystallography data reduction","volume":"43","author":"Winter","year":"2010","journal-title":"J. Appl. Crystallogr."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107988_b0205","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.bioorg.2024.107988_b0210","doi-asserted-by":"crossref","first-page":"s300","DOI":"10.1107\/S0108767313097407","article-title":"CCP4 6.4, the next step in the MX software development and distribution","volume":"69","author":"Lebedev","year":"2013","journal-title":"Acta Crystallogr. A"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107988_b0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. Sect. D: Biol. Crystallogr."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107988_b0220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D: Biol. Crystallogr."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107988_b0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. Sect. D: Biol. Crystallogr."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T21:01:25Z","timestamp":1736456485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824008939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":45,"alternative-id":["S0045206824008939"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107988","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107988"}}